FANCL antibody (C-Term)

Catalog No. ABIN1881336

This anti-FANCL antibody is a Rabbit Polyclonal antibody detecting FANCL in WB. Suitable for Human. This Primary Antibody has been cited in 5+ publications.

Quick Overview for FANCL antibody (C-Term) (ABIN1881336)

Target: FANCL (Fanconi Anemia, Complementation Group L (FANCL))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FANCL antibody is un-conjugated

Application: Western Blotting (WB)

Clone: RB23901

Product Details anti-FANCL Antibody

Binding Specificity: AA 274-302, C-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This FANCL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-302 amino acids from the C-terminal region of human FANCL.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-FANCL antibody (ABIN1881336)

Zhang, Zhao, Park, Wang, Dyer, Liu, Klee, McNiven, Tindall, Molina, Fei: "FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth." in: The Journal of clinical investigation, Vol. 120, Issue 5, pp. 1524-34, (2010) (PubMed).

García, Fernández, Osorio, Barroso, Fernández, Urioste, Benítez et al.: "Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer ..." in: Carcinogenesis, Vol. 30, Issue 11, pp. 1898-902, (2009) (PubMed).

Longerich, San Filippo, Liu, Sung: "FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL." in: The Journal of biological chemistry, Vol. 284, Issue 35, pp. 23182-6, (2009) (PubMed).

McWilliams, Bamlet, de Andrade, Rider, Couch, Cunningham, Matsumoto, Rabe, Hammer, Petersen: "Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, Issue 9, pp. 2549-52, (2009) (PubMed).

Hess, Ameziane, Schuurhuis, Errami, Denkers, Kaspers, Cloos, Joenje, Reinhardt, Ossenkoppele, Zwaan, Waisfisz: "Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia." in: Cellular oncology : the official journal of the International Society for Cellular Oncology, Vol. 30, Issue 4, pp. 299-306, (2008) (PubMed).

Target Details for FANCL

Target: FANCL (Fanconi Anemia, Complementation Group L (FANCL))

Alternative Name: FANCL

Background: The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity, they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms.

Molecular Weight: 42905

NCBI Accession: NP_001108108, NP_060532

UniProt: Q9NW38

Pathways: DNA Damage Repair